Peripheral blood biomarkers in development that use DNA methylation could predict endoscopic response to treatment with adalimumab, vedolizumab, and ustekinumab for patients with Crohn s disease.
Britain s agency that determines if medicines should be used in the National Health Service said on Thursday it is speeding up how it decides if COVID-19 therapies are still effective against circulating variants.